Supplementary Material for: Lung adenocarcinoma size decrease after SARS-CoV-2 vaccination during long-term pembrolizumab treatment: A case report
收藏DataCite Commons2023-09-13 更新2024-08-18 收录
下载链接：
https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Lung_adenocarcinoma_size_decrease_after_SARS-CoV-2_vaccination_during_long-term_pembrolizumab_treatment_A_case_report/24083241/1
下载链接
链接失效反馈官方服务：
资源简介：
A man in his late 40s was diagnosed with clinical stage IVB lung adenocarcinoma with a PD-L1 tumor proportion score of 100% and high tumor mutational burden. A partial response was achieved after administration of pembrolizumab. The patient received two doses of a SARS-CoV-2 vaccine (BNT162b2) after 59 courses, and a chest CT revealed consolidation in the peri-tumoral area, which subsequently disappeared, and the tumor continued to shrink in the next four months. This case provides indirect evidence for the persistence of cancer immunity during long-term treatment with immune checkpoint inhibitors and the potential for further activation.
提供机构：
Karger Publishers
创建时间：
2023-09-13
